Denis Viglietti

List of Publications by Year in descending order

17 papers	1,311 citations	567281 15 h-index	839539 18 g-index
18 all docs	18 docs citations	18 times ranked	1901 citing authors

#	Article	IF	Citations
1	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. JAMA Internal Medicine, 2019, 179, 1365.	5.1	125
2	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney International, 2019, 96, 189-201.	5.2	117
3	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell–mediated rejection. American Journal of Transplantation, 2019, 19, 1972-1988.	4.7	60
4	Recognition of i-IF/TA as a component of the T cell-mediated rejection spectrum: Unselected population approach vs random case selection. American Journal of Transplantation, 2018, 18, 771-772.	4.7	3
5	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. Journal of the American Society of Nephrology: JASN, 2018, 29, 620-635.	6.1	94
6	T cell–mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. American Journal of Transplantation, 2018, 18, 377-390.	4.7	76
7	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney International, 2018, 94, 773-787.	5.2	38
8	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Medicine, 2018, 15, e1002572.	8.4	76
9	Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney International, 2017, 92, 729-742.	5.2	43
10	Value of Donor–Specific Anti–HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. Journal of the American Society of Nephrology: JASN, 2017, 28, 702-715.	6.1	111
11	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
12	Biomarkers of IgA vasculitis nephritis in children. PLoS ONE, 2017, 12, e0188718.	2.5	63
13	Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation. Current Opinion in Organ Transplantation, 2016, 21, 433-440.	1.6	11
14	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 293-304.	6.1	244
15	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, The, 2015, 351, h3557.	6.0	146
16	Determinants and Outcomes of Accelerated Arteriosclerosis. Circulation Research, 2015, 117, 470-482.	4.5	41
17	Perirenal fluid collections and monoclonal gammopathy. Nephrology Dialysis Transplantation, 2012, 27, 448-449.	0.7	18